Back to today’s briefing

Story perspectives

Obesity Drug Switch Leaves Thousands in Limbo

5/19/2025

29 4

Summary

Story summary

Tens of thousands of Americans face a daunting switch from the effective obesity drug Zepbound to Wegovy, driven by insurance restrictions stemming from undisclosed agreements between drugmakers and pharmacy benefit managers. Despite research showing Zepbound's superior weight loss results, CVS Health’s Caremark has opted to cut it from coverage, leaving many in a tough spot.

1 of 1

Story summary

Tens of thousands of Americans face a daunting switch from the effective obesity drug Zepbound to Wegovy, driven by insurance restrictions stemming from undisclosed agreements between drugmakers and pharmacy benefit managers. Despite research showing Zepbound's superior weight loss results, CVS Health’s Caremark has opted to cut it from coverage, leaving many in a tough spot.